IP Library › Granted Patent US 8,637,483
Granted Patent B2
US 8,637,483 · App. 13/509,331 · Granted Jan 28, 2014

Antisense molecules and methods for treating pathologies

Inventors: Stephen Donald Wilton (Applecross, AU); Sue Fletcher (Bayswater, AU); Abbie Adams (Kalamunda, AU); Penny Meloni (Mount Hawthorne, AT)
Assignee: The University of Western Australia
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,483
App. No.
13/509,331
Granted
Jan 28, 2014
Kind
B2
Abstract

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Claims (66)

1. A combination of two or more antisense molecules selected from the following combinations:

(a) an antisense oligonucleotide comprising SEQ ID NO: 31 and an antisense oligonucleotide comprising SEQ ID NO: 32;

(b) an antisense oligonucleotide comprising SEQ ID NO: 33 and an antisense oligonucleotide comprising SEQ ID NO: 34;

(c) an antisense oligonucleotide comprising SEQ ID NO: 35 and an antisense oligonucleotide comprising SEQ ID NO: 36;

(d) an antisense oligonucleotide comprising SEQ ID NO: 39, an antisense oligonucleotide comprising SEQ ID NO: 40, and an antisense oligonucleotide comprising SEQ ID NO: 41;

(e) an antisense oligonucleotide comprising SEQ ID NO: 42 and an antisense oligonucleotide comprising SEQ ID NO: 43;

(f) an antisense oligonucleotide comprising SEQ ID NO: 44 and an antisense oligonucleotide comprising SEQ ID NO: 45;

(g) an antisense oligonucleotide comprising SEQ ID NO: 46 and an antisense oligonucleotide comprising SEQ ID NO: 47;

(h) an antisense oligonucleotide comprising SEQ ID NO: 48 and an antisense oligonucleotide comprising SEQ ID NO: 49; and

(i) an antisense oligonucleotide comprising SEQ ID NO: 50 and an antisense oligonucleotide comprising SEQ ID NO: 51,

wherein each of the antisense oligonucleotides comprises a modification to minimize or prevent cleavage by RNase H, and wherein the combination of antisense molecules is capable of binding to selected targets in dystrophin pre-mRNA to induce exon skipping in the human dystrophin gene.

2. The antisense molecules according to claim 1 , capable of binding to selected target sites, wherein the target site is an mRNA splicing element selected from a splice donor site, splice acceptor sites or exonic splicing enhancer elements.

3. A pharmaceutical composition for the treatment of muscular dystrophy in a patient comprising (a) a combination of antisense molecules according to claim 1 , and (b) one or more pharmaceutically acceptable carriers and/or diluents.

4. A method of treating muscular dystrophy in a patient comprising administering to the patient a pharmaceutical composition according to claim 3 .

5. A kit comprising a combination of antisense molecules according to claim 1 , a suitable carrier and instructions for it's use.

6. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 31 and an antisense oligonucleotide comprising SEQ ID NO: 32, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

7. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 33 and an antisense oligonucleotide comprising SEQ ID NO: 34, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

8. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 35 and an antisense oligonucleotide comprising SEQ ID NO: 36, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

9. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 39, an antisense oligonucleotide comprising SEQ ID NO: 40, and an antisense oligonucleotide comprising SEQ ID NO: 41, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

10. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 42 and an antisense oligonucleotide comprising SEQ ID NO: 43, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

11. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 44 and an antisense oligonucleotide comprising SEQ ID NO: 45, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

12. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 46 and an antisense oligonucleotide comprising SEQ ID NO: 47, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

13. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 48 and an antisense oligonucleotide comprising SEQ ID NO: 49, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

14. The combination of claim 1 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 50 and an antisense oligonucleotide comprising SEQ ID NO: 51, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

15. The combination of claim 1 , wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

16. The combination of claim 1 , wherein the antisense oligonucleotides comprise a nucleobase modification or nucleobase substitution.

17. The combination of claim 1 , wherein the antisense oligonucleotides comprise a modified backbone.

18. The combination of claim 1 , wherein the antisense oligonucleotides comprise non-natural inter-nucleoside linkages.

19. The combination of claim 1 , wherein the antisense oligonucleotides comprise modified backbones in which the inter-nucleotide bridging phosphate residues are modified phosphates.

20. The combination of claim 19 , wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.

21. The combination of claim 1 , wherein the antisense oligonucleotides are 2′-O-methyl-oligoribonucleotides.

22. The combination of claim 1 , wherein the antisense oligonucleotides are peptide nucleic acids.

23. The combination of claim 1 , wherein the antisense oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.

24. The combination of claim 1 , wherein the antisense oligonucleotides are conjugated to a polyamine.

25. The combination of claim 1 , wherein the antisense oligonucleotides are chemically linked to a polyethylene glycol chain.

26. A pharmaceutical composition comprising a combination of antisense molecules according to claim 6 , and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising a combination of antisense molecules according to claim 7 , and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a combination of antisense molecules according to claim 8 , and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising a combination of antisense molecules according to claim 9 , and a pharmaceutically acceptable carrier.

30. A pharmaceutical composition comprising a combination of antisense molecules according to claim 10 , and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising a combination of antisense molecules according to claim 11 , and a pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising a combination of antisense molecules according to claim 12 , and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising a combination of antisense molecules according to claim 13 , and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising a combination of antisense molecules according to claim 14 , and a pharmaceutically acceptable carrier.

35. The method of claim 4 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

36. A method of treating muscular dystrophy in a patient comprising administering an effective amount of a combination of two or more antisense molecules selected from the following combinations:

(a) an antisense oligonucleotide comprising SEQ ID NO: 31 and an antisense oligonucleotide comprising SEQ ID NO: 32;

(b) an antisense oligonucleotide comprising SEQ ID NO: 33 and an antisense oligonucleotide comprising SEQ ID NO: 34;

(c) an antisense oligonucleotide comprising SEQ ID NO: 35 and an antisense oligonucleotide comprising SEQ ID NO: 36;

(d) an antisense oligonucleotide comprising SEQ ID NO: 39, an antisense oligonucleotide comprising SEQ ID NO: 40 and an antisense oligonucleotide comprising SEQ ID NO: 41;

(e) an antisense oligonucleotide comprising SEQ ID NO: 42 and an antisense oligonucleotide comprising SEQ ID NO: 43;

(f) an antisense oligonucleotide comprising SEQ ID NO: 44 and an antisense oligonucleotide comprising SEQ ID NO: 45;

(g) an antisense oligonucleotide comprising SEQ ID NO: 46 and an antisense oligonucleotide comprising SEQ ID NO: 47;

(h) an antisense oligonucleotide comprising SEQ ID NO: 48 and an antisense oligonucleotide comprising SEQ ID NO: 49; and

(i) an antisense oligonucleotide comprising SEQ ID NO: 50 and an antisense oligonucleotide comprising SEQ ID NO: 51,

wherein each of the antisense oligonucleotides comprises a modification to minimize or prevent cleavage by RNase H, and wherein the combination of antisense molecules is capable of binding to a selected target in dystrophin pre-mRNA to induce exon skipping in the human dystrophin gene.

37. The method of claim 36 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

38. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 31 and an antisense oligonucleotide comprising SEQ ID NO: 32, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

39. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 33 and an antisense oligonucleotide comprising SEQ ID NO: 34, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

40. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 35 and an antisense oligonucleotide comprising SEQ ID NO: 36, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

41. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 39, an antisense oligonucleotide comprising SEQ ID NO: 40, and an antisense oligonucleotide comprising SEQ ID NO: 41, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

42. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 42 and an antisense oligonucleotide comprising SEQ ID NO: 43, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

43. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 44 and an antisense oligonucleotide comprising SEQ ID NO: 45, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

44. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 46 and an antisense oligonucleotide comprising SEQ ID NO: 47, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

45. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 48 and an antisense oligonucleotide comprising SEQ ID NO: 49, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

46. The method of claim 36 , wherein the antisense molecules are an antisense oligonucleotide comprising SEQ ID NO: 50 and an antisense oligonucleotide comprising SEQ ID NO: 51, and wherein the antisense oligonucleotides comprise deoxyribonucleotide or ribonucleotide sequences.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: WILTON, STEPHEN DONALD; FLETCHER, SUE; ADAMS, ABBIE; MELONI, PENNY
To: THE UNIVERSITY OF WESTERN AUSTRALIA
Reel/Frame 028246/0861 →
Priority Claims (1)
AU 2009905549 · Nov 12, 2009 · national
Continuity (1)
Related Publication 20120270925A1 · Oct 25, 2012